Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have been given a consensus recommendation of “Buy” by ...

Context Therapeutics Inc.’s CNTX share price has surged by 13.22%, which has investors questioning if this is right time to ...

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies.

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Antibody-drug conjugate specialist TORL has ... an ADC targeting claudin 6 (CLDN6) that has cleared a phase 1 trial and is en route to a phase 2 study in CLDN6-positive, platinum-resistant ovarian ...

After hours: March 25 at 7:57:53 PM EDT Loading Chart for CNTX ...

The study focuses on CLDN6-positive ovarian, endometrial, and testicular cancers ... This leadership change comes as the company continues to focus on its portfolio of bispecific antibodies targeting ...